To test whether TME2.TcellResponse indeed captures this characteristic of tumor-infiltrating CD8+ T cells, we read out the scores of TME2.TcellResponse signature in two subgroups of dysfunction CD8+ T cells isolated from tumors and chronic viral infection: terminally exhausted tumor-infiltrating CD8+ T cells that can no longer respond to anti-PD-1 therapy and progenitor exhausted tumor-infiltrating CD8+ T cells that can still respond to anti-PD-1 therapy (GSE122713) (Miller et al., 2019; Busselaar et al., 2020). Here, PDCD1 is linked to neoplasm.